LEADER 01065nam0 22002653i 450 001 SUN0091169 005 20121002011418.572 010 $a88-7425-004-5 100 $a20121001d2002 |0itac50 ba 101 $aita 102 $aIT 105 $a|||| ||||| 200 1 $aˆI ‰signori del castello di Traetto$fMario Rizzi$gprefazione di Renato Filippelli 210 $aMarina di Minturno$cCaramanica$d2002 215 $a163 p.$cill.$d24 cm. 620 $dMarina di Minturno$3SUNL000346 700 1$aRizzi$b, Mario$3SUNV073859$0723036 702 1$aFilippelli$b, Renato$3SUNV073860 712 $aCaramanica$3SUNV001357$4650 801 $aIT$bSOL$c20181109$gRICA 912 $aSUN0091169 950 $aBIBLIOTECA DEL DIPARTIMENTO DI ARCHITETTURA E DISEGNO INDUSTRIALE$d01 PREST IBc84 $e01 51738 995 $aBIBLIOTECA DEL DIPARTIMENTO DI ARCHITETTURA E DISEGNO INDUSTRIALE$bIT-CE0107$h51738$kPREST IBc84$op$qa 996 $aSignori del castello di Traetto$91409630 997 $aUNICAMPANIA LEADER 04883nam 22006255 450 001 9910300311103321 005 20200705034942.0 010 $a3-319-62710-4 024 7 $a10.1007/978-3-319-62710-6 035 $a(CKB)4100000000587396 035 $a(DE-He213)978-3-319-62710-6 035 $a(MiAaPQ)EBC5085010 035 $a(PPN)204534623 035 $a(EXLCZ)994100000000587396 100 $a20170930d2018 u| 0 101 0 $aeng 135 $aurnn|008mamaa 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aActive Surveillance for Localized Prostate Cancer $eA New Paradigm for Clinical Management /$fedited by Laurence Klotz 205 $a2nd ed. 2018. 210 1$aCham :$cSpringer International Publishing :$cImprint: Humana,$d2018. 215 $a1 online resource (XII, 250 p. 39 illus., 27 illus. in color.) 225 1 $aCurrent Clinical Urology,$x2197-7194 311 $a3-319-62709-0 320 $aIncludes bibliographical references at the end of each chapters and index. 327 $aCancer Overdiagnosis and Overtreatment -- Can We Screen and Still Reduce Overdiagnosis? -- The Role of Fear in Overdiagnosis and Overtreatment -- Ethical and Legal Considerations in Active Surveillance for Prostate Cancer -- Gleason 6 Tumors Should Still Be Labeled As Cancer -- Risk Based Selection for Active Surveillance -- Surveillance at the Margins: Management of High Volume Gleason 6, PSA > 10, or Gleason 3+4 -- How Should Patients on Active Surveillance be Followed? -- Triggers for Intervention -- MR Imaging in Prostate Tumor Volume Assessment: How Accurate? -- Can MRI Replace Biopsy in Men on Surveillance? -- Tissue Based Markers for Risk Prediction -- International AS Registry: The Movember Foundation?s Global Action Plan Prostate Cancer Active Surveillance Initiative -- Better Informed Decision Making to Optimize Patient Selection -- How Does QOL Compare Between Surveillance and Active Treatment? -- The Potential Benefits of Diet and Physical Activity among Active Surveillance Patients with Low-Burden Prostate Cancer -- Is there a Role for Pharmacologic Manipulation to Prevent Progression in Men on Active Surveillance? The Role of 5-ARIs, Statins, and Metformin -- The Update of Active Surveillance around the World: Utilization and Outcomes -- Tissue Preservation ? Active Surveillance and Focal Therapy as Complimentary Strategies -- The Economics of Active Surveillance for Prostate Cancer -- Research Questions in Active Surveillance. 330 $aThis fully updated and revised new edition provides a comprehensive, state-of-the art review of this field, and will serve as a valuable resource for clinicians, surgeons and researchers with an interest in prostate cancer. The book reviews new data about molecular characteristics of the disease, profiles the new grading system for prostate cancer introduced in 2015, and provides new perspectives about imaging of prostate cancer, as well as the role of targeted biopsies. The text summarizes the role of biomarkers and MRI in patient selection and management and details the world wide results of active surveillance. Specific chapters address communication and ethical issues, QOL outcomes, economic aspects, and psycho-social aspects of surveillance. The role of focal therapy for low risk disease is summarized, and the data supporting preventive interventions during surveillance reviewed. This text will serve as a very useful resource for physicians and researchers dealing with, and interested in this common malignancy, as it provides a concise yet comprehensive summary of the current status of the field that will help guide patient management and stimulate investigative efforts. . 410 0$aCurrent Clinical Urology,$x2197-7194 606 $aUrology 606 $aOncology 606 $aRadiology 606 $aGeriatrics 606 $aUrology$3https://scigraph.springernature.com/ontologies/product-market-codes/H62002 606 $aOncology$3https://scigraph.springernature.com/ontologies/product-market-codes/H33160 606 $aImaging / Radiology$3https://scigraph.springernature.com/ontologies/product-market-codes/H29005 606 $aGeriatrics/Gerontology$3https://scigraph.springernature.com/ontologies/product-market-codes/H33150 615 0$aUrology. 615 0$aOncology. 615 0$aRadiology. 615 0$aGeriatrics. 615 14$aUrology. 615 24$aOncology. 615 24$aImaging / Radiology. 615 24$aGeriatrics/Gerontology. 676 $a616.99463 702 $aKlotz$b Laurence$4edt$4http://id.loc.gov/vocabulary/relators/edt 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910300311103321 996 $aActive Surveillance for Localized Prostate Cancer$91742343 997 $aUNINA